Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ALVAC gp100 vaccine

A vaccine composed of the replication-defective plaque purified recombinant canarypox virus (ALVAC) that encodes the glycoprotein 100 (gp100) gene, with potential antineoplastic activity. Vaccination with ALVAC gp100 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for the gp100 melanoma antigen, resulting in decreased tumor growth.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ALVAC gp-100 vaccine gp100 ALVAC vaccine

ALVAC gp100 vaccine

Search NCI's Drug Dictionary